What New KRAS Drug Data From ESMO 2026 Mean for Patients
Roche's divarasib showed improved survival and tumor shrinkage in NSCLC patients with KRAS G12C mutation compared to approved drugs. Lilly's olomorasib, combined with Keytruda, showed promising results in early trials. Rasonque (Incyte) extended life in pancreatic cancer patients. All drugs have side effects, with diarrhea common.
How this was made
The 30-second read
Why it matters
These data represent the first public disclosure of phase 3 outcomes for divarasib and early combination data for olomorasib, providing fresh material for investors.
Market read
First‑time reporting of pivotal trial data for KRAS inhibitors, likely to move biotech equities.
What to watch
Potential safety concerns, pricing pressures, and the need for FDA approval timelines could temper enthusiasm.
Background
The article summarizes new clinical trial results presented at the 2026 European Society for Medical Oncology meeting, focusing on KRAS‑targeted therapies.
Ticker impact
Eli Lilly's investigational KRAS G12C drug olomorasib, combined with Keytruda, showed 55% 18‑month PFS in early data and received FDA breakthrough therapy designation.
moderate upside as market anticipates later‑stage data.
Breakthrough designation and encouraging early results can boost sentiment, though data are still early.
Incyte reported early-stage activity of its KRAS G12D inhibitor INCB161734 in a 54‑patient study, showing tumor shrinkage.
limited impact pending further data.
Early study size is small; investors will wait for larger trials.
Market effects
Strengthens the oncology biotech sector and may lift peers developing KRAS inhibitors.
Positive for US biotech stocks and European pharma ADRs.
Highlights continued investment in targeted cancer therapies worldwide.
Counterpoint
Skeptics may argue that early data do not guarantee commercial success and that competition from existing KRAS drugs remains fierce.
Key entities
- CompanyRoche
Developer of divarasib, presented phase 3 results.
- CompanyEli Lilly
Developer of olomorasib, received breakthrough designation.
- CompanyIncyte
Developer of INCB161734, early KRAS G12D inhibitor.
